Upregulation of the cell-cycle regulator RGC-32 in epstein-barr virus-immortalized cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Schlick, Sandra N ^a,b   Wood, C David ^a   Gunnell, Andrea ^a   Webb, Helen M ^a   Khasnis, Sarika ^a   Schepers, Aloys ^a,c   West, Michelle J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b RESEARCH CENTER BORSTEL   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1C; UNCLASSIFIED DRUG; VIRUS PROTEIN; CELL CYCLE PROTEIN; MUSCLE PROTEIN; NERVE PROTEIN; RGC32 PROTEIN, HUMAN; RUNX1 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; OVARY CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPONSE GENE TO COMPLEMENT 32; RGC 32 GENE; RIBOSOME; RNA ANALYSIS; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; TRANSLATION REGULATION; UPREGULATION; VIRUS GENE; VIRUS TRANSFORMATION; VIRUS VIRULENCE; BIOSYNTHESIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; METABOLISM; METHODOLOGY; PLASMID; POLYSOME; PROTEIN SYNTHESIS; TUMOR CELL LINE; VIROLOGY;

B-LYMPHOCYTES; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; PLASMIDS; POLYRIBOSOMES; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 82755192438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028638     Document Type: Article

References (77)

1. Pope JH, Horne MK, Scott W, (1968) Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3: 857-866.
2. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
3. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, et al. (2004) Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101: 239-244.
4. Babcock GJ, Thorley-Lawson DA, (2000) Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci U S A 97: 12250-12255.
5. O'Nions J, Allday MJ, (2003) Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22: 7181-7191.
6. O'Nions J, Turner A, Craig R, Allday MJ, (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80: 12408-12413.
7. Cannell EJ, Farrell PJ, Sinclair AJ, (1998) Cell cycle arrest following exposure of EBV-immortalised B-cells to gamma irradiation correlates with inhibition of cdk2 activity. FEBS Lett 439: 297-301.
8. Wade M, Allday MJ, (2000) Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 20: 1344-1360.
9. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, et al. (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342-1353.
10. Leao M, Anderton E, Wade M, Meekings K, Allday MJ, (2007) Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 81: 248-260.
11. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, et al. (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13: 2541-2549.
12. Parker GA, Touitou R, Allday MJ, (2000) Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19: 700-709.
13. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500-19505.
14. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919-1924.
15. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421-433.
16. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ, (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
17. Knight JS, Sharma N, Kalman DE, Robertson ES, (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78: 12857-12867.
18. Knight JS, Robertson ES, (2004) Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78: 1981-1991.
19. Knight JS, Sharma N, Robertson ES, (2005) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25: 1749-1763.
20. Knight JS, Sharma N, Robertson ES, (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A 102: 18562-18566.
21. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES, (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81: 6718-6730.
22. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, et al. (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82: 4082-4090.
23. Yi F, Saha A, Murakami M, Kumar P, Knight JS, et al. (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236-247.
24. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652-4669.
25. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, et al. (2011) Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 7: e1001275.
26. Saha A, Bamidele A, Murakami M, Robertson ES, (2011) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85: 2079-2088.
27. Badea TC, Niculescu FI, Soane L, Shin ML, Rus H, (1998) Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem 273: 26977-26981.
28. Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, et al. (2002) RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem 277: 502-508.
29. Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, et al. (2009) Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol 86: 87-94.
30. Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, et al. (2007) RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 26: 1110-1121.
31. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
32. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, et al. (2004) Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065-8077.
33. Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, et al. (2005) Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol 78: 116-122.
34. Vlaicu SI, Tegla CA, Cudrici CD, Fosbrink M, Nguyen V, et al. (2010) Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 88: 67-76.
35. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, et al. (2006) Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24: 274-287.
36. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
37. Kim DS, Lee JY, Lee SM, Choi JE, Cho S, et al. (2011) Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. Cancer 117: 590-596.
38. Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, et al. (2008) Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp (Warsz) 56: 115-122.
39. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, et al. (1991) Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349: 612-614.
40. Spender LC, Cornish GH, Sullivan A, Farrell PJ, (2002) Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol 76: 4919-4927.
41. Spender LC, Whiteman HJ, Karstegl CE, Farrell PJ, (2005) Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. Oncogene 24: 1873-1881.
42. Park ES, Choi S, Muse KN, Curry TE Jr, Jo M, (2008) Response gene to complement 32 expression is induced by the luteinizing hormone (LH) surge and regulated by LH-induced mediators in the rodent ovary. Endocrinology 149: 3025-3036.
43. Jo M, Curry TE Jr, (2006) Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. Mol Endocrinol 20: 2156-2172.
44. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, et al. (2008) Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 27: 5856-5866.
45. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
46. Maier S, Staffler G, Hartmann A, Hock J, Henning K, et al. (2006) Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 80: 9761-9771.
47. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979.
48. Oram SW, Liu XX, Lee TL, Chan WY, Lau YF, (2006) TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer 6: 154.
49. Lau YF, Lau HW, Komuves LG, (2003) Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. Cytogenet Genome Res 101: 250-260.
50. Lau YF, (1999) Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am J Hum Genet 64: 921-927.
51. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, et al. (2005) Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856-1867.
52. Yin YH, Li YY, Qiao H, Wang HC, Yang XA, et al. (2005) TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer 93: 458-463.
53. Ferby I, Blazquez M, Palmer A, Eritja R, Nebreda AR, (1999) A novel p34(cdc2)-binding and activating protein that is necessary and sufficient to trigger G(2)/M progression in Xenopus oocytes. Genes Dev 13: 2177-2189.
54. Lenormand JL, Dellinger RW, Knudsen KE, Subramani S, Donoghue DJ, (1999) Speedy: a novel cell cycle regulator of the G2/M transition. Embo J 18: 1869-1877.
55. Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, et al. (2002) Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. J Cell Biol 157: 357-366.
56. Cheng A, Solomon MJ, (2008) Speedy/Ringo C regulates S and G2 phase progression in human cells. Cell Cycle 7: 3037-3047.
57. Gastwirt RF, McAndrew CW, Donoghue DJ, (2007) Speedy/RINGO regulation of CDKs in cell cycle, checkpoint activation and apoptosis. Cell Cycle 6: 1188-1193.
58. Jakowlew SB, (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457.
59. Blyth K, Cameron ER, Neil JC, (2005) The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
60. Cohen MM Jr, (2009) Perspectives on RUNX genes: an update. Am J Med Genet A 149A: 2629-2646.
61. Brady G, Whiteman HJ, Spender LC, Farrell PJ, (2009) Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation. J Virol 83: 6909-6916.
62. Cameron JE, Fewell C, Yin Q, McBride J, Wang X, et al. (2008) Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology 382: 257-266.
63. Fox M, Urano J, Reijo Pera RA, (2005) Identification and characterization of RNA sequences to which human PUMILIO-2 (PUM2) and deleted in Azoospermia-like (DAZL) bind. Genomics 85: 92-105.
64. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, et al. (2010) Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 141: 129-141.
65. Galgano A, Forrer M, Jaskiewicz L, Kanitz A, Zavolan M, et al. (2008) Comparative analysis of mRNA targets for human PUF-family proteins suggests extensive interaction with the miRNA regulatory system. PLoS One 3: e3164.
66. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64: 2309-2318.
67. Menezes J, Leibold W, Klein G, Clements G, (1975) Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22: 276-284.
68. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, et al. (1977) Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer 19: 27-33.
69. West MJ, Webb HM, Sinclair AJ, Woolfson DN, (2004) Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol 78: 9431-9445.
70. King W, Thomas-Powell AL, Raab-Traub N, Hawke M, Kieff E, (1980) Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol 36: 506-518.
71. Sinclair AJ, Palmero I, Peters G, Farrell PJ, (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. Embo J 13: 3321-3328.
72. Ritzi M, Tillack K, Gerhardt J, Ott E, Humme S, et al. (2003) Complex protein-DNA dynamics at the latent origin of DNA replication of Epstein-Barr virus. J Cell Sci 116: 3971-3984.
73. Topisirovic I, Capili AD, Borden KL, (2002) Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner. Mol Cell Biol 22: 6183-6198.
74. West MJ, Lowe AD, Karn J, (2001) Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 75: 8524-8537.
75. Bark-Jones SJ, Webb HM, West MJ, (2006) EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5. Oncogene 25: 1775-1785.
76. West MJ, Sullivan NF, Willis AE, (1995) Translational upregulation of the c-myc oncogene in Bloom's syndrome cell lines. Oncogene 11: 2515-2524.
77. Johannes G, Sarnow P, (1998) Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. Rna 4: 1500-1513.